NUNAGEN
NUNAGEN
DEVELOPMENT ROADMAP
From Platforms to Patients
NUNAGEN’s synthetic genome platforms translate complex clinical needs into a robust development roadmap, accelerating the journey from lab-scale synthesis to patient-side therapeutic delivery.
Current Programs
PROGRAMME
INDICATION
STAGE
NGEN-101
Viral Infection - Prophylactic
Pre-clinicals
NGEN-204
Viral Infection - Prophylactic & Treatment
In vitro POC
Future Programs
NUNAGEN is continuously expanding its platform capabilities. These discovery-stage programs represent our next generation of synthetic genome innovation, designed to address the world’s most pressing medical challenges.
Platform Extension
Extended biocatalytic modules targeting cancer and autoimmune diseases with high-precision.
Discovery Asset
Novel assembly building blocks designed for multi-valent tumur targeting and chemotherapy.
Multivalent vaccine
Multivalent vaccine for broaden protection, limit escape variants and enable rapid updates as new strains emerge.
Partnering for Impact
NUNAGEN is currently raising a pre-seed round to advance its synthetic genome platforms through key preclinical milestones. Our investment and partnership strategy focuses on working with mission-aligned investors, pharma and biotech partners, and leading academic centres to validate our platforms in high-impact indications. We aim to combine capital, domain expertise and strategic collaborations to accelerate translation while building a sustainable, globally scalable therapeutic model.
- Proven KCL Spinout Scalability
- Proprietary Biocatalytic Platform Assets
- Significant ESG & Sustainability Impact
- Clear Commercial Development Roadmap